©1995 by The American Society for Biochemistry and Molecular Biology, Inc.
Major Histocompatibility Complex Class II-associated Invariant Chain Gene Expression Is Up-regulated by Cooperative Interactions of Sp1 and NF-Y (*)

(Received for publication, May 16, 1995; and in revised form, June 21, 1995)

Kenneth L. Wright (§) Terry L. Moore (¶) Barbara J. Vilen (**) Adrienne M. Brown (§§) , Jenny P.-Y. Ting(¶¶)

From the From Lineberger Comprehensive Cancer, Department of Microbiology-Immunology, University of North Carolina, Chapel Hill, North Carolina 27599-7295

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
REFERENCES

ABSTRACT

Expression of the major histocompatibility complex (MHC) class II-associated invariant chain (Ii) is required for efficient and complete presentation of antigens by MHC class II molecules and a normal immune response. The Ii gene is generally co-regulated with the MHC class II molecules at the level of transcription and a shared SXY promoter element has been described. This report defines the proximal promoter region of Ii which may regulate Ii transcription distinct from MHC class II. In vivo genomic footprinting identified an occupied, imperfect CCAAT box and an adjacent GC box in the proximal region. These sites are bound in Ii-ositive cell lines and upon interferon- induction of Ii transcription. In contrast, both sites are unoccupied in Ii-egative cell lines and in inducible cell lines prior to interferon- treatment. Together these two sites synergize to stimulate transcription. Independently, the transcription factor NF-Y binds poorly to the imperfect CCAAT box with a rapid off rate, while Sp1 binds to the GC box. Stabilization of NF-Y binding occurs upon Sp1 binding to DNA. In addition, the half-life of Sp1 binding also increased in the presence of NF-Y binding. These findings suggest a mechanism for the complete functional synergy of the GC and CCAAT elements observed in Ii transcription. Furthermore, this report defines a CCAAT box of imperfect sequence which binds NF-Y and activates transcription only when stabilized by an adjacent factor, Sp1.


INTRODUCTION

One of the central steps in elicitation of an immune response is the presentation of foreign antigenic peptides by the major histocompatibility complex (MHC) (^1)class II molecules on the surface of cells(1, 2) . Recognition of the peptidebulletMHC class II complex by the T-cell receptor on class II-restricted T lymphoid cells leads to activation of the T cells and the initiation of the immune response(3, 4) . Binding of peptides to the class II molecules is regulated in part by the MHC class II-associated invariant chain (Ii) protein(5, 6) . The Ii is an integral membrane protein which associates with class II alpha/beta molecules in the endoplasmic reticulum(7, 8) . This association has multiple affects on class II molecules, all of which optimize the binding and presentation of foreign peptides derived from the extracellular environment (reviewed in Refs. 9, 10). The Ii also appears to play a role in targeting the class II molecules to endosomal or endosomal-like compartments where peptide is bound(11, 12, 13, 14) . The critical role of Ii was demonstrated in mutant mice lacking a functional Ii gene(15, 16) . MHC class II function was impaired resulting in inefficient antigen presentation and a deficiency in CD4+ T cells.

The tight functional association of Ii and class II is reflected in their coordinate transcriptional regulation. Both molecules are only expressed in a select group of cells including B cells, activated human T cells, thymic epithelial cells, and macrophages(17, 18, 19) . Ii and class II are also coordinately induced by interferon- (IFN-) in several cell types including macrophages and brain glial cells (20, 21, 22, 23) . The Ii promoter and the class II promoters share a common DNA motif, S/X/Y, which interacts with at least three distinct transcription factors(4, 24, 25, 26) . Several studies have clearly demonstrated that this motif is responsible for both the constitutive and IFN--induced coordinate regulation(27, 28, 29, 30) . In class II promoters, this motif is located proximal to the TATA box and is generally sufficient for transcriptional activation. In contrast, the Ii promoter has over 170 base pairs (bp) between the TATA box and the S/X/Y motif. There are several cases of differential regulation between Ii and class II genes(17, 18, 31, 32) . The additional Ii promoter sequences between the S/X/Y and TATA domains may harbor elements mediating the discordant transcription. In the murine Ii promoter, an NF-kappaB site has been identified which mediates basal and TNFalpha induction of Ii transcription(33) . In addition, promoter deletion analysis implicated a GC box as important for the basal activity of the murine gene(30) . Recently, two NF-kappaB sites have been characterized at position -172 and -118 base pairs of the human Ii promoter(34) . The function of these elements is dependent on cell type-specific differences in the binding of NF-kappaB subunits. Despite these studies, little is known about the Ii proximal promoter and the factors bound there which may be required for transcription as well as potentially mediating the effects of the distal S/X/Y motif.

The Y box of the S/X/Y motif is an inverted CCAAT site which binds the heteromeric transcription factor NF-Y (also known as CBF, CP1, and YEBP)(35, 36, 37, 38) . NF-Y is clearly distinct from the other known CCAAT box-binding proteins, CTF/NF-1 and C/EBP. NF-Y is composed of an A, B, and C subunit of 42, 36, and 40 kDa, respectively(39, 40) . NF-Y is highly conserved through evolution(41) . The yeast transcription factors HAP3, HAP2, and HAP5 are homologues of the A, B, and C subunits, respectively, and are functionally interchangeable in a DNA binding assay(42) . In addition to MHC class II promoters, NF-Y-binding sites are found in many unrelated promoters; e.g. HSV-tk (37) , collagen(36) , and albumin(43) . Typically the binding sites are located in the proximal promoter region between -60 and -80 base pairs upstream of the transcription initiation site(44) . Functional analysis has also shown that NF-Y can be important in transcription reinitiation as well as in activation, suggesting a role in basal transcription(43, 45) .

In the MHC class II promoters, NF-Y also functions to stabilize and/or recruit additional transcription factors to the S/X/Y complex. In vitro, NF-Y and the X box-binding protein, RFX, co-stabilize binding to their DNA sites(46) . Furthermore, in vivo mutation of the NF-Y-binding site abrogates factor binding to the upstream X1 and X2 sites(47) . In addition, NF-Y requires that the DNA stereospecifically align the X and Y boxes for activation(48) . NF-Y has also been studied at the serum albumin promoter and in that context functions synergistically with C/EBP to activate transcription(43) . The interaction between these factors partially destabilizes NF-Y binding but results in a large synergistic increase in the formation of stable preinitiation complexes. These studies of NF-Y suggest that although found in many different promoters, its mode of function may depend upon the local environment of that specific promoter.

In this report we now describe the in vivo characterization of the elements and factors involved at the proximal promoter of the human Ii gene. Through the use of in vivo genomic footprinting, two adjacent binding sites with homology to a GC box and an imperfect CCAAT box are identified. The GC and CCAAT elements act synergistically to promote Ii transcription and are bound by the transcription factors Sp1 and NF-Y, respectively. NF-Y and Sp1 bind cooperatively at the Ii promoter to mediate, at least in part, the observed functional synergy. Thus, maximal Ii transcription requires the action of two NF-Y factors; one in the distal S/X/Y motif and one described here in a cooperative binding complex with Sp1 in the proximal promoter. These findings describe a mechanism of transcriptional activation by the ubiquitous transcription factor NF-Y and define a new promoter region regulating Ii expression.


EXPERIMENTAL PROCEDURES

DNA Constructs

The invariant chain promoter, chloramphenicol acetyltransferase (CAT) reporter gene construct, 790IiCAT, contains the human Ii promoter sequences from +1 to -790 base pairs relative to the transcription initiation site(49) . Mutant constructs were derived by oligonucleotide-directed, site-specific mutagenesis as described previously(50) . The construct 790IimtGC changed the sequence at -74 to -65 bp from 5`-TGGGCGGAGT-3` to 5`-TGtttGGAGT-3`. The construct 790IimtYprox changed the sequence at -50 to -42 bp from 5`-CGAATCAGAT-3` to 5`-CGAcgCtcAT-3`. The double mutant construct, 790IimtGC/Yprox, contained the changes in both sites as described for the single mutants. All mutations were confirmed by DNA sequencing.

Cell Culture, Transient Transfection, and CAT Aassay

Raji is a human Epstein-Barr virus-positive Burkitt's lymphoma cell line that expresses high levels of Ii gene and MHC class II antigens. H9 (HuT78) was derived from a human T cell lymphoma and also expresses high levels of Ii gene and MHC class II antigens. Jurkat is a T lymphoblastoid cell line which does not express Ii or MHC class II genes. These cells were grown in RPMI 1640 supplemented with 8% fetal calf serum and 2 mM glutamine. The human glioblastoma multiform cell line, U105-MG, which was previously referred to as U373-MG in this laboratory was grown in McCoy's 5A supplemented with 10% fetal calf serum and 2 mM glutamine. Interferon- induction of U105-MG cells used 500 units/ml and was generously provided by Biogen (Cambridge, MA). Transient transfections of the Raji cells were performed by electroporation as described previously(51) . The transfectants were harvested 24 h following electroporation. Expression of the transiently transfected reporter genes was assayed by quantitating chloramphenicol acetyltransferase activity in cell extracts as described previously (51) . CAT activity was resolved on thin layer chromatography plates and quantitated with a Molecular Dynamics PhosphorImager (Sunnyvale, CA).

In Vivo Footprinting

In vivo methylation of cells and DNA preparation were as described by Pfeifer et al.(52) . The ligation-mediated, polymerase chain reaction amplified in vivo genomic footprinting was as originally described by Mueller and Wold (53) and modified by Wright and Ting (54) . The primer set utilized to reveal the Ii proximal promoter, upper strand is: UPP1, 5`-ATTGTTGGAGATAAGGTCG-3`; UPP2, 5`-ATGACTGGCTTCTGATCTTCCCGACAGC; UPP3, 5`-ACTGGCTTCTGATCTTCCCGACAGCTCCTG-3`. The primer set utilized to reveal the Ii proximal promoter, lower strand is: LPP1, 5`-GCCCAGAAACAAGTGATGAG-3`; LPP2, 5`-GGATCGTGCTGGCCTTTCTACCTGC-3`; LPP3, 5`-GGATCGTGCTGGCCTTTCTACCTGCCTG-3`.

Nuclear Extract Preparation and Gel Shift Analysis

Nuclear extracts were prepared according to Dignam et al.(55) from Raji cells grown in suspension to a density of 8 10^5 cells/ml. Gel shift analysis was performed as described previously (56) . The wild type Ii oligonucleotide, IiGC/Yprox, spanned from -82 to -32 bp of the promoter relative to the transcription initiation site. The sequence is shown in Fig. 1C. The IiYprox oligonucleotide contains a mutation of the GC box and is 5`-CATCTACCAAGTGtttGGAGTGGCCTTCTGTGGACGAATCAGATTCCTCTCCAG-3`. The Ii GC oligonucleotide contains a mutation in the Y-proximal site and is 5`-CATCTACCAAGTGGGCGGAGTGGCCTTCTGTGGACGAcgCtcATTCCTCTCCAG-3`. The DRA Y box oligonucleotide is 5`-ATTTTTCTGATTGGCCAAAGATTT-3`. The consensus Sp1-binding site oligonucleotide is 5`-GTCACCGGGGCGGGGCGGTCAC-3`. The DRA octa oligonucleotide is 5`-AGAGTAATTGATTTGCATTTTAATGGTCAG-3`. The TAATGARAT consensus OTF-1-binding site oligonucleotide was derived from the HSV IE45 promoter and is 5`-TTCACGCGGTAATGAGATGGGTT-3`. Antibody supershift experiments were performed by preincubating 1 µg of antibody for 2 h on ice with each binding reaction prior to the addition of the DNA probe. The NF-YA and NF-YB antibodies have been reported previously (47) . The Sp1 and NF-kappaB-p50 antibodies were purchased from Santa Cruz Inc. (Santa Cruz, CA).


Figure 1: In vivo protein-/DNA interactions at the Ii gene proximal promoter reveal an occupied GC box and imperfect NF-Y site. A, In vivo footprint analysis of the upper strand of the Ii proximal promoter. Cont., control in vitro methylated deproteinized DNA; In vivo, in vivo methylated DNA. Open arrows, protections; solid arrows, enhancements. Weak interactions are depicted by arrowheads. The functional elements as defined in this report are indicated by brackets on the left. The Raji B cell line and the H9 T cell line constitutively express Ii, and the contact points at the GC box and Y-proximal site are the same. The Ii-negative Jurkat T cell line only displayed a single weak protection at position -50. B, lower strand in vivo footprint analysis. Lane markings are the same as in panel A. Five protections were detected across the GC box and Y-proximal site in the constitutively expressing Raji and H9 cell lines. No contacts were detected in Ii negative Jurkat cell line. C, sequence of the Ii proximal promoter and summary of the in vivo contact points. The functional elements are indicated by shaded boxes and the arrows and arrowheads are as in panels A and B.



Relative DNA Binding Affinity and Half-life Determination

The relative DNA binding affinity constants of the Sp1bulletNF-Y complex compared to either Sp1 or NF-Y alone was calculated from EMSA competition gels as described previously in detail(57) . Briefly, gel shift binding reactions with increasing amounts of specific competitor DNA (0-500-fold molar excess) were allowed to come to equilibrium and then separated by non-denaturing gel electrophoresis. The amount of complexed and free probe was measured by PhosphorImage analysis. Assuming, where P is the DNA-binding protein and C is the proteinbulletDNA complex, [DNA] [P] then [DNA] =[DNA]


RESULTS

In Vivo Genomic Footprinting Reveals an Occupied GC Box and an Imperfect CCAAT Box

Several studies by our laboratory and others have characterized transcriptional elements present in the distal promoter region of the Ii gene. However, little is known about the identity or requirement for proximal elements. We directly addressed this question by mapping the DNA sequences occupied in intact cells by in vivo genomic footprinting. In vivo footprinting allows the visualization of protein-DNA interactions on endogenous genes in the more physiologically relevant intact cell. Fig. 1displays the footprints for the first 90 base pairs of the Ii promoter in cell lines consitutively positive for Ii expression, Raji and H9 and an Ii-negative cell line, Jurkat. Two very clear domains of contacts were detected in the B lymphoblastoma cell line, Raji and the T lymphoblastoid cell line H9 (Fig. 1, A and B, lanes 1-4 and summarized in Fig. 1C). The contacts in both of these cell lines and in another Ii-expressing B cell line, Namalwa (data not shown) were identical. Five protections and two enhancements on the upper strand were clustered over a sequence with high homology to a consensus GC box. The single guanine residue on the lower strand of this GC box was also protected (Fig. 1B). In addition, two guanine residues flanking the GC box were weakly protected. Downstream of the GC box region a second, weaker clusters of contacts are visible. There is a weak protection at position -56 and a strong protection at -50 on the upper strand. On the lower strand there is a strong protection at -51 and a second weak protection at -39. These contacts partially overlap with a imperfect NF-Y/CCAAT box-binding site. A consensus NF-Y/CCAAT box has previously been characterized in the distal region of the Ii promoter and is referred to as the Y box. Thus we named the imperfect, proximal NF-Y/CCAAT homology, Y-proximal (Y-prox). The weak degree of in vivo protection of the Y-proximal site is consistent with previous in vivo footprint analysis of other consensus NF-Y-binding sites(49, 54) . In addition, protection of the Y-proximal adenine residues at position -45, -48, and -49 was detectable in Raji cells by a modified in vivo footprinting protocol (data not shown, 59). Analysis of the Ii-negative, T lymphoblastoid cell line Jurkat did not detect any protein-DNA interactions at the GC box and Y-proximal elements on the lower strand and only a single weak protection on the upper strand (Fig. 1, A and B, lanes 5 and 6). Our previous in vivo analysis of the distal portion of the Ii promoter also revealed it to be unoccupied in Jurkat cells. The single protection in Jurkat cells could indicate an extremely weak interaction at the Y-proximal site or more likely reflect an alteration of the DNA structure in that area, since the rest of the promoter is unoccupied. A similar bare promoter was observed for the MHC class II promoter DRA in Jurkat cells even though the transcription factors are available in the nucleus(54) . These results suggest that class II and Ii-negative cells may prevent transcription of these genes by blocking the accessibility of transcription factors to the promoters. Furthermore, the class II and Ii genes may use a common mechanism to block accessibility despite their location on different chromosomes.

Ii gene transcription is strongly induced by IFN- in a number of non-lymphoid cell types. In the glioblastoma cell line U105-MG, the induction is mediated through a 5-6-fold increase in the rate of Ii gene transcription(34) . In vivo footprint analysis of the Ii proximal promoter in U105-MG cells revealed no protein-DNA interactions prior to IFN- induction (Fig. 2). Four h after the addition of IFN-, protections are clearly visible at the GC box and Y-proximal site. The contacts are identical to those observed in the Raji and H9 cells. A similar pattern of interaction was observed at 18 and 48 h post-induction. This region of the Ii promoter has not been implicated in the IFN- response; rather two upstream elements, the ISRE and S/X/Y domain, appear to mediate the induction (27, 29, 60) . Analysis of those IFN--responsive elements as well as the two NF-kappaB sites displayed in vivo occupancy only after IFN- treatment(34, 49) . Interestingly, protection at these distal elements did not become maximal until 24 or 48 h post-induction (see ``Discussion''). This indicates that the entire Ii promoter is shielded from transcription factor binding in the uninduced state, and IFN- treatment relieves this repression.


Figure 2: Induction of Ii expression by interferon- induces in vivo protein-DNA interactions at the Ii proximal promoter. The glioblastoma cell line, U105-MG, was treated with 500 units/ml recombinant IFN- and examined by in vivo footprint analysis at the times indicated above each lane. Lane markings are as described in Fig. 1. At time 0 h, no contacts were detected. Interactions at both the GC box and Y-proximal site were clearly detectable at 4 h and continued for 18 and 48 h. The interactions were indistinguishable from those detected in the constitutively expressing B and T cell lines.



The GC Box and Y-proximal Site Synergistically Activate Ii Transcription

We addressed the functional importance of the newly identified in vivo binding sites by preparing site-specific mutants of the recognition sequences and assaying the effect on transcription from the Ii promoter. The GC box was altered by changing the core sequence to three successive T residues. This mutation blocks Sp1 binding to GC boxes as shown previously (61) and below. Four residues were altered in the Y-proximal site which eliminated all potential homology to CCAAT boxes. Each of the mutations were assayed in the context of the 790-base pair Ii promoter fused to the CAT reporter gene. These constructs were first transfected into the constitutively high expressing Raji B cell line. Transcription from the Ii promoter with a mutated GC box is dramatically lowered to 24% of wild type (Fig. 3). A similar loss in activity is detected from the Ii promoter with a mutated Y-proximal site. Significantly, no further reduction in transcription is observed when the both the GC box and Y-proximal site are mutated in one construct (mtGC/Yprox). This finding suggests these elements can not activate independently of each other in the Ii promoter, since neither site alone has activity greater than the double mutant construct. The remaining transcriptional activity is likely to be driven from the distal SXY motif, which alone in the class II DRA gene is sufficient to promote high levels of expression. The Ii double mutant construct was slightly but reproducibly higher than the single GC box mutation. This may indicate that the Y-proximal site in the absence of the GC box represses transcription. The effect of these mutations on the IFN- inducibility of Ii transcription was examined by transfection into U105-MG cell line. All of the mutant constructs were strongly induced by IFN- treatment, although the basal level of expression was lowered (data not shown). This finding provides evidence that these elements are not involved in the IFN- induction pathway. However, in the constitutively expressing cells the GC box and Y-proximal sites are critical for maximal transcription and display complete synergy in activation.


Figure 3: The Ii GC box and Y-proximal site synergize to activate transcription. The wild type (WT) Ii promoter construct contains 790 base pairs of the promoter fused to the CAT reporter gene. Site-specific mutation of the GC box (mtGC), Y-proximal site (mtYprox), or both (mtGC/Yprox) are derived from the wild type parent construct as described under ``Experimental Procedures.'' Constructs were transiently transfected into the Raji B cell line and assayed by CAT activity. The results are normalized to one for expression from the wild type construct. Each bar represents data from seven independent experiments, and the S.E. is indicated by the error bars.



Sp1 Binds at the GC Box and NF-Y Binds at the Imperfect CCAAT Box

In vitro binding studies were utilized to identify the factors interacting with the in vivo identified GC box and Y-proximal site. Oligonucleotides containing both binding sites and corresponding to the region between -32 and -85 of the Ii promoter were assayed by EMSA. Titrating increasing amounts of Raji B-cell nuclear extract into the binding reaction with a constant amount of probe resolved four specific binding activities, labeled A-D (Fig. 4A, lanes 1-4). An identical pattern was detected when nuclear extracts from a second B cell line, Namalwa, were used (data not shown). All of the bands increase in intensity as the amount of nuclear extract is increased. However, the slowest migrating band, D, accumulates most rapidly. At the lowest protein concentration band D is the least abundant complex, but at the highest protein concentration band D represents a significant portion of the total shifted probe. This pattern is consistent with band D representing a multimeric complex composed of two or more of the faster migrating complexes. The specificities of the complexes were identified by oligonucleotide competition. Self-competition with the Ii sequence containing both the GC box and Y-proximal sites (lane 5) abrogated all binding except for the weak nonspecific band (n.s.). Bands D and B were competed by an Ii Y-proximal oligonucleotide (lane 6) while the Ii GC box oligonucleotide competed for the D, C, and A bands (lane 7). An oligonucleotide mutated in both the GC and Y-proximal sites failed to compete for any band (lane 8). Therefore, binding at the Y-proximal site is related to the D and B bands while binding at the GC box is related to the D, C, and A bands. This finding is consistent with the D band representing specific, simultaneous binding at both the GC box and Y-proximal site. The GC box has strong homology to a Sp1-binding site. Competition with a Sp1 consensus binding site oligonucleotide removes bands D, C, and A (lane 9). The resulting pattern is identical to competition with the Ii GC box oligonucleotide and further suggests Sp1 is binding at the Ii GC box. Competition with a high affinity OTF-2-binding site from the MHC class II DRA promoter had no effect on any of the complexes (lane 10).


Figure 4: In vitro binding to the Ii proximal promoter detects complexes with the GC box, the Y-proximal site, and both together. A, EMSA analysis with the wild type Ii probe, IiGC/Yprox (-32 to -85 bp). Shaded triangle indicates increasing amounts of Raji nuclear extract (0.2-2 µg) added to the binding reaction and the shaded rectangle represents a constant 1 µg of nuclear extract. Specific complexes are labeled A-D while n.s. indicates the nonspecific band. Oligonucleotide competitors are indicated above lanes 5-10 and are described under ``Experimental Procedures.'' B, EMSA competition analysis demonstrates that the complex binding to the Y-proximal site is related to NF-Y. The wild type Ii probe (IiGC/Yprox) is used in lanes 1-5, and the high affinity NF-Y site DRA Y-box is used for lanes 6-10.



Although the Y-proximal site is divergent at the highly conserved second C residue of the CCAAT box, the remainder of the sequence conforms to an 11-bp NF-Y consensus. The consensus was derived from 17 different published NF-Y-binding sites (Table 1). The MHC class II DRA Y box is a high affinity NF-Y-binding site and was used in EMSA competition to access the relationship between the Y-proximal binding activity and NF-Y (Fig. 4B). Competition of the Ii GC/Yprox oligonucleotide probe with the DRA Y box eliminated the D and B bands (lane 3). This pattern of competition is identical to competition with the Ii Y-proximal site as shown in Fig. 4A, lane 6. The unrelated DRA octa oligonucleotide did not compete for any of the bands. The Y-proximal site also has weak homology to the OTF-1 binding consensus TAATGARAT. However, none of the Ii-specific bands were competed for by a TAATGARAT oligonucleotide (lane 5). An identical pattern of competition was observed when a probe corresponding to the DRA Y box was used (lanes 6-10). Both Ii GC/Yprox and DRA Y box oligonucleotides competed the NF-Y band. Neither the DRA octa or TAATGARAT competed for the band. Together, the competition results suggest that NF-Y interacts at the Y-proximal site. Furthermore, both NF-Y and Sp1 can bind simultaneously to the Ii promoter as evidenced by the D band.



A direct test for the presence of NF-Y and Sp1 on the Ii promoter is available through the use of antibodies specific for the two transcription factors. Specific antibodies or preimmune sera are added to the EMSA binding reaction and then resolved by gel electrophoresis. A specific antibody interaction either diminishes the gel shift band (blocking) or shifts the complex higher in the gel (supershift). We first tested the antibodies on the wild type Ii probe (Fig. 5, lanes 1-5). The preimmune sera has no effect on any of the complexes. However, the antisera specific for the A subunit of NF-Y results in a supershifted band concomitant with a decrease in the intensity of the D and B bands. This is consistent with the association of the D and B bands with binding at the Y-proximal site. The anti-Sp1 antibody also produced a supershifted complex and diminished the D and C bands. However, the B band was unaffected. This is also consistent with the D and C bands representing GC box binding. An unrelated antibody specific for NF-kappaB-p50 did not effect any of the bands. The antibodies were also assayed on the NF-Y complex derived from the DRA Y box probe (lanes 6-10). Only the antibody specific for NF-YA subunit supershifted the NF-Y complex. To simplify the gel shift-antibody pattern, the same experiment was done with gel shift probes mutated in one or the other binding sites. As shown in lanes 11-15, when the Y-proximal binding activity is present alone only the NF-YA and B antibodies recognize this band (lanes 12 and 13). A probe that contains only the GC box binding activity forms both the A and C bands (lane 16). The antibody specific for Sp1 supershifts the C band but not the A band (lane 19). This confirms the identity of the C band as Sp1, while the much less abundant A band is an immunologically unrelated GC box-binding protein. Combined, the gel shift and antibody reactivity clearly defines NF-Y binding at the Y-proximal site. Furthermore, this indicates Sp1 is the predominant GC box-binding protein, although at this point a role for the A band protein cannot be excluded.


Figure 5: EMSA-antibody supershift analysis identifies NF-Y interacting at the Y-proximal site and Sp1 at the GC box. The antibodies used are indicated above each lane. -, no antibody; PI, preimmune antiserum. The probes used are marked above each gel. Other markings are as described in Fig. 4.



Sp1 and NF-Y Cooperatively Bind to the Ii Promoter by Increasing Their DNA-binding Half-lives

Functional synergy has been reported for a number of different promoters. Several mechanisms have been proposed to account for these synergistic effects, including direct and indirect physical interaction between transcription factors and with the basal transcription machinery. We have initially tested whether the synergism between NF-Y and Sp1 is reflected in cooperative binding to their DNA sites. The relative affinity of the proteins for their DNA-binding sites was approximated by EMSA competition assays (see ``Experimental Procedures'' and (57) for calculations). This approach utilizes the EMSA to quantitate the amount of complex formed in the presence of increasing amounts of specific competitor DNA. The affinity constant can be estimated from a plot of 1/[complex] versus 1/[DNA] (for assumptions, see ``Experimental Procedures''). The value obtained is affected by the complex assay mixture including the crude nuclear extract and nonspecific competitor DNAs which cannot be corrected for. However, under fixed assay conditions the values obtained should be valid with respect to each other. No change was detected in the relative affinity constants for binding of either Sp1 or NF-Y alone compared to the Sp1bulletNF-Y complex (data not shown). We next compared the off-rates of the two proteins alone and in a complex together. In this analysis, EMSA-binding reactions with DNA probes containing either the Ii GC box or Y-proximal site or both together were allowed to reach equilibrium. Specific competitors in excess of 1000-fold were then added. Aliquots of the binding reaction were subsequently loaded onto a continuously electrophoresing gel at 0, 1, 2, 4, 8, 15, and 25 min after competitor addition. The intensities of the specific bands were quantitated by PhosphorImage analysis and plotted as the intensity of the band after competition for a given time over the intensity of the band prior to competition (see ``Experimental Procedures'' for details). The time at which only 50% of the complex is remaining is calculated as the half-life and thus is a measure of the stability of the intaction after the complex is formed. As shown in Fig. 6A, NF-Y binding to the Y-proximal site of Ii is very unstable with a half-life of only 1.7 min. However, when NF-Y binds to the Ii promoter in conjunction with Sp1 binding the half-life of NF-Y increases 4.5-fold. To examine whether the increased stability would be significant, a comparison was made to the consensus NF-Y site from the DRA promoter (Fig. 6B). Similar half-lives were detected for both the functional DRA-NF-Y interaction and the Ii-NF-YbulletSp1 complex. Examination of Sp1 binding to the Ii GC box also revealed a stabilization of binding when in an Sp1bulletNF-Y complex (Fig. 6C). The half-life of Sp1 binding alone was 3.2 min. When present together with NF-Y, the half-life of Sp1 increased to approximately 3-fold. These findings indicate that both factors are stabilized when binding at adjacent sites and suggests a mechanism by which the imperfect Y-proximal element can function as an NF-Y-binding site. Thus, DNA binding cooperativity is one of the underlying sources for the functional synergy observed between Sp1 and NF-Y.


Figure 6: The DNA binding half-lives of NF-Y and Sp1 are stabilized when both factors are complexed with the DNA together. A, off-rate analysis of NF-Y independently bound to the Ii Y-proximal site, t= 1.7 min (squares), or bound as a complex with Sp1 at the Ii proximal promoter, t = 7.5 min (circles). B, comparison of NF-Y binding stability at the consensus DRA-Y box, t = 6.0 min (squares), and the Ii NF-YbulletSp1 complex, t = 7.5 min (circles). C, off-rate analysis of Sp1 bound either independently to the Ii GC box, t = 3.2 min (squares) or in a complex with NF-Y, t = 8.9 min (circles). Where the horizontal line at 50 intersects the plot indicates the calculated half-life for that plot. Values were determined from PhosphorImage analysis of EMSA competition gels as described under ``Experimental Procedures'' and are plotted as the percent of complex shifted over the initial complex formed before competition versus the time of competition. Band D was quantitated for the half-life of Sp1 and NF-Y after competition with either the GC box or a consensus Y-box, respectively (see lane 1, Fig. 5for example gel prior to competition). Band B of the Ii-Y-proximal probe was quantitated for the half-life of NF-Y alone (see lane 11, Fig. 5for example of gel prior to competition). Band C of the Ii GC probe was quantitated for the half-life of Sp1 alone (see lane 16, Fig. 5for example of gel prior to competition). Band ``NF-Y'' of the DRA-Y box probe was quantitated for the half-life of NF-Y on the consensus Y box (see lane 6, Fig. 5for example gel prior to competition). Each point is the average of at least three independent experiments and the S.E. in indicated by the error bars.




DISCUSSION

Control of Ii gene transcription plays a critical role in the presentation of antigens by MHC class II molecules and the maintenance of a normal immune response. This report now defines a new region of the Ii promoter required for expression of this gene. Examination of the in vivo occupancy of the Ii promoter in constitutively expressing cell lines identified a bound GC box and imperfect CCAAT box (Y-proximal) at positions -74 and -53, respectively, relative to the transcription initiation site. Only 11 base pairs or one helical turn of the DNA separate these two recognition sites. In addition, binding at the TATA box at position -24 was detected when an alternative in vivo footprinting protocol was utilized to reveal contacts at adenine residues (data not shown). Combined with our previous studies(34, 49) , these observations now complete the in vivo footprint analysis of the entire 300-base pair Ii promoter. There are eight elements clearly bound in vivo; TATA box (-24 bp), Y-proximal (-53 bp), GC box (-74 bp), ISRE (-96 bp), kappaB-1 (-118 bp), kappaB-2 (kB-2 bp), Y (-207 bp), and X (-236 bp). Additionally, the S element (-260 bp) has been defined functionally but does not display interaction contacts in vivo. This is consistent with the related S element in the class II DRA promoter which also did not show in vivo contacts (54, 62) .

The GC box and Y-proximal sites were occupied in both B and T cell lines which constitutively express Ii. However, neither site was bound in the Ii-negative Jurkat T cell line. The lack of in vivo binding occurs despite the presence of the transacting factors Sp1 and NF-Y in the nuclei of these cells, as detected by in vitro binding assays(34, 54) . (^2)Furthermore, none of the elements within the 300-bp Ii promoter are occupied in vivo in the Ii-negative cell line. However, when the Ii promoter is transiently introduced into these cells, it displays a significant level of transcriptional activity. This finding suggests a higher order inhibition of DNA binding at the endogenous Ii promoter, potentially at the level of chromatin reorganization. This is consistent with the nuclease hypersensitivity studies done on many genes, which demonstrated that inactive genes are often found in condensed, nuclease-resistant regions of the chromatin(63, 64, 65) . Interestingly, the functionally related class II DRA gene promoter is also unoccupied and not expressed in the Jurkat cell line. Although the class II genes are located on a separate chromosome from Ii, a similar mechanism may be responsible for the inaccessibility of these promoters in non-expressing cells.

Interferon- is a potent inducer of Ii and class II transcription (23, 66, 67, 68) . In the IFN--inducible cell line U105-MG, the Ii proximal promoter elements GC and Y-proximal sites are unoccupied prior to the induction. IFN- treatment up-regulates binding at both proximal elements by 4 h, and binding continues at 18 and 48 h after addition IFN-. Loading of the proximal elements appears to occur prior to loading at the distal elements. The distal X and Y boxes display only the very weak beginnings of interaction at 4 h but by 24 h show maximal binding(49) . Loading at the negative Ii element kB-1 appears to be delayed even further, until 48 h. This finding suggests that interactions at the Y-proxmal site and/or the GC box occur first and may be required to open the promoter for additional factor binding. Thus, the Ii promoter minimizes basal level expression by preventing binding of the transacting factors in the uninduced state. This is in direct contrast to the class II DRA gene in which all elements are bound prior to IFN- induction in this cell line(54) . Treatment with IFN- then induces an up-regulation of the weak binding activity at the X box of the DRA S/X/Y domain to a strong interaction. The Ii promoter also utilizes an S/X/Y domain for the IFN- response (27, 29) and to a lesser degree an ISRE element(60) . Thus, the induction pathway for Ii and class II are likely to be highly related. However, the mechanism by which the Ii promoter remains unoccupied until IFN- treatment is unclear. In vivo analysis of several other promoters has revealed situations analogous to both the all or none effect observed for Ii and the limited effect detected for class II DRA (53, 69, 70, 71) . It is somewhat surprising to find two coordinately regulated genes invoking different mechanisms. Interestingly, an in vivo study of the class II DRA promoter demonstrated a central requirement for NF-Y in the loading of the promoter(47) . Stable introduction of a DRA promoter construct with a mutated Y/CCAAT box blocked in vivo binding at all promoter elements in the IFN--induced U105-MG cells. In contrast mutation of the other promoter elements S, X1, and X2 only has a local effect on binding in vivo. The findings from that study implicated the transcription factor NF-Y binding to the Y/CCAAT box as critical for recruitment of the other promoter factors and/or opening the chromatin structure across the promoter region. This has potentially important implications for the Ii promoter since two NF-Y-binding CCAAT boxes are present in this promoter, the distal Y box of the S/X/Y domain and the Y-proximal element. It will be interesting to determine if one or both of these elements modulate accessibility to the Ii promoter.

Synergistic activation by two distinct transcription factors is becoming a common phenomenon and several different mechanisms have been reported (see (72) and references within). This report defines a synergistic activation of Ii transcription by Sp1 bound at the GC box and NF-Y bound at the Y-proximal site. Neither site was capable of activating Ii transcription in the absence of the other site. However, together they formed a strong transcriptional activator. At least one basis for their synergy is that NF-Y binds to the Y-proximal element with a very short half-life. Sp1 also binds to the Ii GC box with a short half-life. Stabilization of both NF-Y and Sp1 binding occurs when Sp1 and NF-Y bind the Ii promoter together. This suggests that in vivo Sp1 and NF-Y may only bind cooperatively to the Ii promoter and thus are completely dependent on each other to activate transcription. In vivo footprint analysis of mutant Ii promoters indicates both sites must be present for binding to occur at either site. (^3)Interestingly, the human multidrug resistance gene MDR has a similar arrangement of GC box and CCAAT box in its proximal promoter(73) . These elements were shown to functionally synergize (^4)although the mechanism has not been investigated. The MDR CCAAT box matches the consensus NF-Y sequence (Table 1), however, stabilization of DNA binding may also play a role in MDR activation.

A number of studies have described cooperative interactions of Sp1 with other factors, but not NF-Y. Examples include OTF-1(74) , C/EBP(75) , NF-kappaB(76) , Ets(77) , E2, YY1(78, 79) , and Sp1(80, 81) . In at least one case a direct physical interaction between Sp1 and the E2 factor was clearly demonstrated even in the absence of an E2 DNA-binding site (82) . In addition, Sp1 can multimerize and thereby synergistically activate transcription(80) . However, in most cases the mechanisms are less well defined. NF-Y has been described in two distinct cooperative interactions. The MHC class II DRA promoter has an NF-Y-binding site which must be stereospecifically aligned with the X box to function (48) . Reith et al.(46) recently demonstrated that stable binding of NF-Y and the X box factor RFX required a cooperative interaction between the two proteins. NF-Y also binds in the serum albumin promoter adjacent to a C/EBP site. The binding of both proteins is required to promote stable preinitiation complex formation(43) . Interestingly, in this case NF-Y DNA binding is weaker in the complex with C/EBP than when alone. Clearly these studies reinforce the hypothesis that synergy can occur through many different mechanisms. In particular, NF-Y appears to have multiple activating functions which are dependent on the local promoter environment.

In conclusion, maximal transcription from the Ii promoter requires a GC box and NF-Y site proximal to the TATA box. These sites function in a synergistic mannar, and it is shown that cooperativity in DNA binding is at least one mechanism underlying the synergy. An additional outcome of this study is the identification of a functional, imperfect NF-Y-binding site that would be undetected in homology searches for the consensus core sequence CCAAT or CAAT. This raises the potential for an even greater usage of NF-Y in promoters that do not have a classical CCAAT box. Finally, the Ii gene exhibits all or none in vivo binding across the promoter in response to IFN- induction. With the previous observations that NF-Y can control access to the DRA promoter in vivo(47) , it will be important to determine if NF-Y plays a similar role for Ii. This could have broad implications for the regulation of multiple genes with an NF-Y/CCAAT box.


FOOTNOTES

*
This work was supported by National Institutes of Health Grants CA48185 and AI29564 and by National Multiple Sclerosis Society Grant RG-185. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
Recipient of a National Institutes of Health training grant postdoctoral fellowship and is an Arthritis Foundation Postdoctoral Fellow.

Present address: Eli Lilly Inc., Indianapolis, IN 46285.

**
Supported by NIH-NIAID Training Grant T32-AI07232. Present address: Dept. Pediatrics, National Jewish Hospital, Denver, CO 80206.

§§
Present address: Molecular Neurobiology Laboratory, The Salk Institute, San Diego, CA 92037.

¶¶
Recipient of an American Cancer Society Faculty Award. To whom correspondence should be addressed: Lineberger Comprehensive Cancer, Dept. of Microbiology-Immunology, CB 7295, University of North Carolina, Chapel Hill, NC 27599-7295. Tel.: 919-966-5538; Fax: 919-966-3015.

(^1)
The abbreviations used are: MHC, major histocompatibility complex; IFN-, interferon-; bp, base pair(s); CAT, chloramphenicol acetyltransferase; EMSA, electrophoretic mobility shift assay.

(^2)
K. L. Wright, unpublished observations.

(^3)
M. Linhoff, personal communication.

(^4)
G. MacDonald, manuscript in preparation.


REFERENCES

  1. Hood, L., Steinmetz, M., and Malissen, B. (1983) Annu. Rev. Immunol. 529-568
  2. Kaufman, J. F., Auffray, C., Korman, A. J., Shackelford, D. A., and Strominger, J. (1984) Cell 36,1-13 [Medline] [Order article via Infotrieve]
  3. Cresswell, P. (1990) Nature 343,593-594 [Medline] [Order article via Infotrieve]
  4. Benoist, C., and Mathis, D. (1990) Annu. Rev. Immunol. 8,681-715 [CrossRef][Medline] [Order article via Infotrieve]
  5. Jones, P. P., Murphy, D. B., Hewgill, D., and McDevitt, H. O. (1978) Immunochemistry 16,51-60
  6. Sant, A. J., and Miller, J. (1994) Curr. Opin. Immunol. 6,57-63
  7. Roche, P., Marks, M., and Cresswell, P. (1991) Nature 354,392-394 [CrossRef][Medline] [Order article via Infotrieve]
  8. Lamb, C., and Cresswell, P. (1992) J. Immunol. 148,3478-3482 [Abstract/Free Full Text]
  9. Cresswell, P. (1992) Curr. Opin. Immunol. 4,87-92
  10. Teyton, L., and Peterson, P. (1992) Trends Cell Biol. 2,52-56 [Medline] [Order article via Infotrieve]
  11. Qiu, Y., Xu, X., Wandinger Ness, A., Dalke, D. P., and Pierce, S. K. (1994) J. Cell Biol. 125,595-605 [Abstract]
  12. Amigorena, S., Drake, J. R., Webster, P., and Mellman, I. (1994) Nature 369,113-120 [CrossRef][Medline] [Order article via Infotrieve]
  13. Tulp, A., Verwoerd, D., Dobberstein, B., Ploegh, H. L., and Pieters, J. (1994) Nature 369,120-126 [CrossRef][Medline] [Order article via Infotrieve]
  14. West, M. A., Lucocq, J. M., and Watts, C. (1994) Nature 369,147-151 [CrossRef][Medline] [Order article via Infotrieve]
  15. Viville, S., Neefjes, J., Lotteau, V., Dierich, A., Lemeur, M., Ploegh, H., Benoist, C., and Mathis, D. (1993) Cell 72,635-648 [Medline] [Order article via Infotrieve]
  16. Bikoff, E. K., Huang, L. Y., Episkopou, V., van Meerwijk, J., Germain, R. N., and Robertson, E. J. (1993) J. Exp. Med. 177,1699-1712
  17. Koch, N., and Harris, A. W. (1984) J. Immunol. 132,12-15
  18. Momburg, F., Koch, N., Moller, P., Moledanhauer, G., Butcher, G. W., and Hammerling, G. J. (1986) J. Immunol. 136,940-948 [Abstract/Free Full Text]
  19. Rahmsdorf, H. J., Koch, N., Mallick, U., and Herrlich, P. (1983) EMBO J. 6,811-816
  20. Koch, N., Wong, G. H. W., and Schrader, J. W. (1984) J Immunol. 132,1361-1369 [Abstract/Free Full Text]
  21. Collins, T., Korman, A. J., Wake, C. T., Boss, J. M., Kappes, D. J., Fiers, W., Ault, K. A., Gimbrone, M. A., Strominger, J. L., and Pober, J. S. (1984) Proc. Natl. Acad. Sci. U. S. A. 81,4917-4921 [Abstract]
  22. Paulnock King, D., Sizer, K. C., Freund, Y. R., Jones, P. P., and Parnes, J. R. (1985) J. Immunol. 135,632-636
  23. Takiguchi, M., Ting, J. P., Buessow, S. C., Boyer, C., Gillespie, Y., and Frelinger, J. A. (1985) Eur. J. Immunol. 15,809-814
  24. Ting, J. P., and Baldwin, A. S. (1993) Curr. Opin. Immunol. 5,8-16
  25. Glimcher, L. H., and Kara, C. J. (1992) Annu. Rev. Immunol. 10,13-49
  26. Peterlin, B. M., Andersson, G., Lotsher, E., and Tsang, S. (1990) Immunol. Res. 9,164-177 [Medline] [Order article via Infotrieve]
  27. Brown, A. M., Barr, C. L., and Ting, J. P. (1991) J. Immunol. 146,3183-3189
  28. Doyle, C., Ford, P. J., Ponath, P. D., Spies, T., and Strominger, J. L. (1990) Proc. Natl. Acad. Sci. U. S. A. 87,4590-4594 [Abstract]
  29. Eades, A. M., Litfin, M., and Rahmsdorf, H. J. (1990) J. Immunol. 144,4399-4409
  30. Zhu, L., and Jones, P. P. (1990) Mol. Cell. Biol. 10,3906-3916 [Medline] [Order article via Infotrieve]
  31. Momburg, F., Koretz, K., von Herbay, A., and Moller, P. (1988) Clin. Exp. Immunol. 72,367-372 [Medline] [Order article via Infotrieve]
  32. dePreval, C., Lisowska-Grospierre, B., Loche, M., Griscelli, C., and Mach, B. (1985) Nature 318,291-293 [Medline] [Order article via Infotrieve]
  33. Pessara, U., and Koch, N. (1990) Mol. Cell. Biol. 10,4146-4154 [Medline] [Order article via Infotrieve]
  34. Brown, A. M., Linhoff, M. W., Stein, B., Wright, K. L., Baldwin, A. S. J., Basta, P. V., and Ting, J. P. (1994) Mol. Cell. Biol. 14,2926-2935 [Abstract]
  35. Chodosh, L. A., Baldwin, A. S., Carthew, R. W., and Sharp, P. A. (1988) Cell 53,11-24 [Medline] [Order article via Infotrieve]
  36. Maity, S. N., Golumbek, P. T., Karsenty, G., and deCrombrugghe, B. (1988) Science 241,582-585 [Medline] [Order article via Infotrieve]
  37. Zeleznik Le, N. J., Azizkhan, J. C., and Ting, J. P. (1991) Proc. Natl. Acad. Sci. U. S. A. 88,1873-1877 [Abstract]
  38. Dorn, A., Bollekens, J., Staub, A., Benoist, C., and Mathis, D. (1987) Cell 50,863-872 [Medline] [Order article via Infotrieve]
  39. Maity, S. N., Sinha, S., Ruteshouser, E. C., and de Crombrugghe, B. (1992) J. Biol. Chem. 267,16574-16580 [Abstract/Free Full Text]
  40. Sinha, S., Maity, S. N., Lu, J., and de Crombrugghe, B. (1995) Proc. Natl. Acad. Sci. U. S. A. 92,1624-1628 [Abstract]
  41. Hooft van Huijsduijnen, R., Li, X. Y., Black, D., Matthes, H., Benoist, C., and Mathis, D. (1990) EMBO J. 9,3119-3127 [Abstract]
  42. Chodosh, L. A., Olsen, J., Hahn, S., Baldwin, A. S., Guarente, L., and Sharp, P. A. (1988) Cell 53,25-35 [Medline] [Order article via Infotrieve]
  43. Milos, P. M., and Zaret, K. S. (1992) Genes & Dev. 6,991-1004
  44. Bucher, P. (1990) J. Mol. Biol. 212,563-578
  45. Mantovani, R., Pessara, U., Tronche, F., Li, X. Y., Knapp, A. M., Pasquali, J. L., Benoist, C., and Mathis, D. (1992) EMBO J. 11,3315-3322 [Abstract]
  46. Reith, W., Siegrist, C. A., Durand, B., Barras, E., and Mach, B. (1994) Proc. Natl. Acad. Sci. U. S. A. 91,554-558 [Abstract]
  47. Wright, K. L., Vilen, B. J., Itoh-Lindstrom, Y., Moore, T. L., Li, G., Criscitiello, M., Cogswell, P., Badley Clark, J., and Ting, J. P.-Y. (1994) EMBO J. 13,4042-4053 [Abstract]
  48. Vilen, B. J., Cogswell, J. P., and Ting, J. P. (1991) Mol. Cell. Biol. 11,2406-2415 [Medline] [Order article via Infotrieve]
  49. Brown, A. M., Wright, K. L., and Ting, J. P. (1993) J. Biol. Chem. 268,26328-26333
  50. Kunkel, T., Roberts, J., and Zakour, T. (1987) Methods Enzymol. 154,367-382 [Medline] [Order article via Infotrieve]
  51. Sherman, P. A., Basta, P. V., Moore, T. L., Brown, A. M., and Ting, J. P.-Y. (1989) Mol. Cell. Biol. 9,50-56 [Medline] [Order article via Infotrieve]
  52. Pfeifer, G. P., Tanguay, R. L., Steigerwald, S. D., and Riggs, A. D. (1990) Genes & Dev. 4,1277-1287
  53. Mueller, P. R., and Wold, B. (1989) Science 246,780-786 [Medline] [Order article via Infotrieve]
  54. Wright, K. L., and Ting, J. P. (1992) Proc. Natl. Acad. Sci. U. S. A. 89,7601-7605 [Abstract]
  55. Dignam, J. D., Lebovitz, R. M., and Roeder, R. G. (1983) Nucleic Acids Res. 11,1475-1488 [Abstract]
  56. Wright, K. L., Dell'Orco, R. T., van Wijnen, A. J., Stein, J. L., and Stein, G. S. (1992) Biochemistry 31,2812-2818 [Medline] [Order article via Infotrieve]
  57. Delvoye, N. L., Destroismaisons, N. M., and Wall, L. A. (1993) Mol. Cell. Biol. 13,6969-6983 [Abstract]
  58. Li, R., Knight, J., Bream, G., Stenlund, A., and Botchan, M. (1989) Genes & Dev. 3,510-526
  59. Strauss, E. C., Andrews, N. C., Higgs, D. R., and Orkin, S. H. (1992) Mol. Cell. Biol. 12,2135-2142 [Abstract]
  60. Barr, C. L., and Saunders, G. F. (1991) J. Biol. Chem. 266,3475-3481
  61. Jones, K. A., Kadonaga, J. T., Luciw, P. A., and Tjian, R. (1986) Science 232,755-759 [Medline] [Order article via Infotrieve]
  62. Kara, C. J., and Glimcher, L. H. (1991) Science 252,709-712 [Medline] [Order article via Infotrieve]
  63. Wu, C. (1980) Nature 286,854-860 [Medline] [Order article via Infotrieve]
  64. Weintraub, H., and Groudine, M. (1976) Science 193,848-856 [Medline] [Order article via Infotrieve]
  65. McGhee, J. D., Wood, W. I., Dolan, M., Engle, J. D., and Felsenfeld, G. (1981) Cell 27,45-55 [Medline] [Order article via Infotrieve]
  66. Pober, J. S., Gimbrone, M. A., Cotran, R. S., Reiss, C. S., Burakoff, S. J., Fiers, W., and Ault, K. A. (1983) J. Exp. Med. 157,1339-1353 [Abstract]
  67. Houghton, A. N., Thomson, T. M., Gross, D., Oettgen, H. F., and Old, L. J. (1984) J. Exp. Med. 160,255-269
  68. Sasaki, A., Levison, S. W., and Ting, J. P. (1990) J. Neuroimmunol. 29,213-222 [Medline] [Order article via Infotrieve]
  69. Herrera, R. E., Shaw, P. E., and Nordheim, A. (1989) Nature 340,68-70 [CrossRef][Medline] [Order article via Infotrieve]
  70. Cordingley, M. G., Riegel, A. T., and Hager, G. L. (1987) Cell 48,261-270 [Medline] [Order article via Infotrieve]
  71. Garrity, P. A., Chen, D., Rothenberg, E. V., and Wold, B. J. (1994) Mol. Cell. Biol. 14,2159-2169 [Abstract]
  72. Herschlag, D., and Johnson, F. B. (1993) Genes & Dev. 7,173-179
  73. Goldsmith, M. E., Madden, M. J., Morrow, C. S., and Cowan, K. H. (1993) J. Biol. Chem. 268,5856-5860 [Abstract/Free Full Text]
  74. Janson, L., and Pettersson, U. (1990) Proc. Natl. Acad. Sci. U. S. A. 87,4732-4736 [Abstract]
  75. Lee, Y. H., Yano, M., Liu, S. Y., Matsunaga, E., Johnson, P. F., and Gonzalez, F. J. (1994) Mol. Cell. Biol. 14,1383-1394 [Abstract]
  76. Perkins, N. D., Edwards, N. L., Duckett, C. S., Agranoff, A. B., Schmid, R. M., and Nabel, G. J. (1993) EMBO J. 12,3551-3558 [Abstract]
  77. Gegonne, A., Bosselut, R., Bailly, R. A., and Ghysdael, J. (1993) EMBO J. 12,1169-1178 [Abstract]
  78. Lee, J. S., Galvin, K. M., and Shi, Y. (1993) Proc. Natl. Acad. Sci. U. S. A. 90,6145-6149 [Abstract]
  79. Seto, E., Lewis, B., and Shenk, T. (1993) Nature 365,462-464 [CrossRef][Medline] [Order article via Infotrieve]
  80. Courey, A. J., Holtzman, D. A., Jackson, S. P., and Tjian, R. (1989) Cell 59,827-836 [Medline] [Order article via Infotrieve]
  81. Anderson, G. M., and Freytag, S. O. (1991) Mol. Cell. Biol. 11,1935-1943 [Medline] [Order article via Infotrieve]
  82. Li, R., Knight, J. D., Jackson, S. P., Tjian, R., and Botchan, M. R. (1991) Cell 65,493-505 [Medline] [Order article via Infotrieve]
  83. Dorn, A., Durand, B., Marfing, C., Le Meur, M., Benoist, C., and Mathis, D. (1987) Proc. Natl. Acad. Sci. U. S. A. 84,6249-6253 [Abstract]
  84. Szabo, S. J., Gold, J. S., Murphy, T. L., and Murphy, K. M. (1993) Mol. Cell. Biol. 13,4793-4805 [Abstract]
  85. Danilition, S. L., Fredrickson, R. M., Taylor, C. Y., and Miyamoto, N. G. (1991) Nucleic Acids Res. 19,6913-6922 [Abstract]
  86. Cohen, R. B., Sheffery, M., and Kim, C. G. (1986) Mol. Cell Biol. 6,821-832 [Medline] [Order article via Infotrieve]
  87. Faber, M., and Sealy, L. (1990) J. Biol. Chem. 265,22243-22254 [Abstract/Free Full Text]
  88. Currie, R. A., and Eckel, R. H. (1992) Arch. Biochem.Biophys. 298,630-639 [Medline] [Order article via Infotrieve]
  89. Groyer-Schweizer, G., Groyer, A., Cadepond, F., Grange, T., Baulieu, E.-E., and Pictet, R. (1992) J. Steroid Biochem. Mol. Biol. 41,747-752 [Medline] [Order article via Infotrieve]
  90. Framson, P., and Bornstein, P. (1993) J. Biol. Chem. 268,4989-4996 [Abstract/Free Full Text]

©1995 by The American Society for Biochemistry and Molecular Biology, Inc.